kabutan

STELLA PHARMA, Net Income Forecast for the Fiscal Year Loss Widened in Downward Revision

Tue Oct 14, 2025 2:00 pm JST Revision

4888 STELLA PHARMA CORPORATION 【J-GAAP】

Guidance Update Report

STELLA PHARMA CORPORATION <4888> [TSE Growth] announced a performance revision in the afternoon session on October 14th (14:00). The net income/loss (non-consolidated) forecast for the fiscal year ending March 2026 has been revised downward from an expected loss of 348 million yen to a loss of 911 million yen (compared to a loss of 140 million yen in the previous period), indicating an expansion in the loss margin.

Furthermore, The company continued to decline to disclose its earnings forecast for April to September (first half).

Kabutan News

Guidance Update

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Prev 1,007 -348 -345 -348 -10.2 0 May 9, 2025 J-GAAP
Mar, 2026 New 377 -922 -908 -911 -26.8 0 Oct 14, 2025 J-GAAP
Revision Rate -62.6% -164.9% -163.2% -161.8% -161.7%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 169 -269 -267 -268 -8.2 0 Nov 8, 2024 J-GAAP
Apr - Sep, 2025 Guidance ー ー ー ー － 0 May 9, 2025 J-GAAP
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 269 -760 -760 -763 -24.7 0 May 10, 2024 J-GAAP
Mar, 2025 961 -90 -137 -140 -4.2 0 May 9, 2025 J-GAAP
Mar, 2026 Guidance 377 -922 -908 -911 -26.8 0 Oct 14, 2025 J-GAAP
YoY -60.8% -924.4% -562.8% -550.7% -534.4%

Related Articles